|
Home
|
|
Symptoms
|
|
Live Discussion
|
|
Diagnosis
|
|
Treatment
|
|
World-wide Support Finder
|
|
Books/Video
|
|
RESEARCH
|
|
Lymelinks
|
|
Contact
|
|
Pets & Lyme
|
|
DONATIONS
|
|
Drug Info
|
|
Medical Dictionary
|
|
Board of Directors
|
Click on the graphic to vote for this
site as a Starting Point Hot Site.
|
|
|
No Warranties or Representations
Lyme Disease symptoms vary from person to person. (lymes disease lyme's disease lime disease limes disease)
The data and information presented in this web site are presented in good faith and believed to be accurate regarding Lyme disease (commonly misspelled lymes disease lyme's disease lime disease limes disease) and other related diseases. Any and all liability for the content or any omissions including any inaccuracies, errors, or misstatements in such data or information is expressly disclaimed. The web site is compiled for the sole purpose of informing community members of resources and information pertaining to Lyme Borreliosis Disease and its coinfections. Lyme disease symptoms may vary from person to person.
The Canadian Lyme Disease Foundation, Directors and members are not liable for any direct or indirect damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action arising out of or in connection with the use or performance of information available from this website.
Consult a qualified Lyme ( Borreliosis ) Disease literate doctor for medical advice if Lyme Disease is suspect to discuss your Lymes Disease Symptoms.
|
Int J Med Microbiol. 2007 Jan 16;
Immune responses to borrelial VlsE IR(6) peptide variants.
* Sillanpaa H,
* Lahdenne P,
* Sarvas H,
* Arnez M,
* Steere A,
* Peltomaa M,
* Seppala I.
Department of Bacteriology and Immunology, Haartman Institute,
Helsinki, Finland.
Laboratory confirmation of Lyme borreliosis (LB) relies mainly on
the demonstration of anti-borrelial antibodies. In recent studies, a
novel VlsE protein IR(6) peptide-based assay has been introduced. Our
aim was to evaluate the IR(6)peptides from three Borrelia burgdorferi
sensu lato genospecies in the serodiagnosis of European and North
American patients. Five VlsE protein IR(6) peptide variants representing
sequences from B. burgdorferi sensu stricto, B. garinii, and B. afzelii
were used as antigens in both IgG and IgM enzyme-linked immunosorbent
assays (ELISA).
Serum antibodies of 187 patients at different stages of
LB from Europe and the United States were evaluated for serodiagnosis.
For comparison samples were tested with one of the commercial IR(6)
ELISAs. Three B. afzelii IR(6) variant peptides revealed antibodies that
were concordant with each other. B. burgdorferi sensu stricto peptide
antibodies mostly paralleled B. afzelii peptide antibodies, and positive
values were also obtained in the majority of European sera. For several
sera, B. garinii IR(6) peptide antibodies were discordant to B. afzelii
peptide antibodies. The commercial IR(6) peptide antibody assay (C6
ELISA) results correlated better with B. burgdorferi sensu stricto IR(6)
than with B. garinii IR(6) peptide IgG results, especially in sera from
patients with facial palsy.
Thus, antibody specificity to IR(6)peptides
may vary according to the infecting Borrelia species. In some
manifestations of the disease, C6 ELISA may not cover all LB cases.
Evidently, the methodological aspects in ELISA design for peptide
antibody measurements are important as well as the amino acids sequence
of the antigen.
TOP
|
|
| | |
